PFIZER-MYLAN COMBO VIATRIS TO REDUCE WORKFORCE BY 9,000

Highlights

• In the month of November, the US pharmaceutical giant Pfizer had joined hands with Mylan to create generics business Viatris

• As per the plan, Viatris by the year 2024 has a target of raising a minimum of $1 billion from its cost base, and it’s pl...

Biocon, Mylan launch hormone biosimilar in Australia

Biotechnology major Biocon, and company Mylan N V  announced the launch of their hormone biosimilar for the treatment of the polygenic disorder, in Australia.

“We are extraordinarily excited to alter reasonable access to Semglee, a high-quality biosimilar hormone glargine, co...